Sunshine Heart, Inc. (NASDAQ: SSH) today announced a major milestone for its flagship C-Pulse device. As of today, C-Pulse has been implanted in 25 patients in North America and Germany, representing a cumulative 25 years of active C-Pulse heart failure treatment, or over one billion inflation and deflation cycles. The 25th patient was implanted on June 14, 2013 at German Heart Institute – Berlin (DHZB).
Press Releases & News
The medical field is constantly changing and innovating. Keep up-to-date with the latest news about C-Pulse® and Sunshine Heart here.
Sunshine Heart, Inc. (NASDAQ: SSH) today announced that it has been awarded an Australian International Design Award in the Medical and Scientific category for its second-generation C-Pulse driver. Sunshine Heart, along with contract development partners, Design + Industry and Hydrix Services, collectively submitted an award application in March. Final awards were presented May 30, 2013 in Sydney, Australia.
The implant of the first patient in the OPTIONS HF C-Pulse System Multicenter Study. The post market study is intended to treat patients with moderate to severe heart failure.
Sunshine Heart, Inc. (NASDAQ: SSH; ASX: SHC), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced it has received unconditional approval from the FDA to commence its pivotal U.S. trial for its flagship C-Pulse® Heart Assist System
Sunshine Heart Receives 2012 Frost & Sullivan North American Heart Failure Treatment New Product Innovation Award for C-Pulse®
Sunshine Heart has received the 2012 North American Heart Failure Treatment New Product Innovation Award. This award highlights the innovation and potential value of Sunshine Heart’s flagship C-Pulse® Heart Assist System.